Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2025
0mins
Should l Buy IDXX?
Source: NASDAQ.COM
Earnings Performance: Integra LifeSciences reported quarterly earnings of $0.45 per share, exceeding estimates and showing a surprise of +4.65%, although down from $0.63 per share a year ago. The company also generated revenues of $415.61 million, surpassing expectations by 5.05%.
Market Outlook: Despite underperforming the market with a 45.5% decline this year, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and industry outlook, as the Medical - Instruments sector is currently ranked in the bottom 40% of industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 617.200
Low
750.00
Averages
792.78
High
850.00
Current: 617.200
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEXX Laboratories Reports Strong Q4 2025 Earnings Amid Target Revisions
- Strong Performance: IDEXX Laboratories reported Q4 2025 revenue of $1.09 billion, a 14% increase year-over-year, surpassing analyst expectations of $1.072 billion, demonstrating robust performance in the medical technology sector.
- Earnings Per Share Growth: The company’s earnings per share rose 18% to $3.08, exceeding the market estimate of $2.93, reflecting its sustained profitability and a gross margin of 61.7%.
- Core Business Growth: The companion animal segment grew 15% to $998 million, driven by strong instrument revenue, which surged 76% year-over-year, indicating robust market demand.
- Cautious Future Outlook: While IDEXX expects 2026 revenue between $4.63 billion and $4.72 billion, BTIG analysts noted a 200-basis-point drag from fewer pet visits among lower-income owners, although a 4% global price growth is anticipated.
See More
IDXX Options Trading Analysis and Risks
- Options Selling Risk: Selling puts on IDXX does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, necessitating careful risk-reward assessment.
- Yield Analysis: If IDXX's stock does not fall by 11.5%, the put seller only earns an 8.5% annualized return, with an effective cost basis of $540 per share after accounting for transaction costs.
- Historical Volatility: IDXX's historical volatility stands at 41%, and when combined with fundamental analysis, it aids investors in determining whether selling puts at the $560 strike price is worthwhile, balancing risks against potential rewards.
- Market Trading Dynamics: On Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
IDEXX Laboratories Reports Strong Q4 Results and 2026 Outlook
- Earnings Beat: IDEXX Laboratories reported Q4 2025 earnings of $3.08 per share, an 18% year-over-year increase that surpassed the consensus estimate of $2.94, indicating robust performance in the animal health sector.
- Sales Growth: The company achieved sales of $1.091 billion in Q4, exceeding the consensus of $1.073 billion and reflecting a 14% year-over-year growth, particularly driven by strong demand in the CAG Diagnostics segment.
- 2026 Outlook: IDEXX forecasts earnings per share for fiscal 2026 to be between $14.29 and $14.80, slightly above the consensus of $14.39, demonstrating confidence in future growth prospects.
- Analyst Rating Adjustments: BTIG analyst lowered the price target for IDEXX from $830 to $800 while maintaining a Buy rating, and UBS analyst reduced the target from $750 to $730 with a Neutral rating, reflecting a cautious market sentiment regarding the company's outlook.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Market Sentiment Improves as Stocks Rise
- Improved Market Sentiment: The CNN Money Fear & Greed Index rose to 61.2 on Monday from 56.1, indicating a shift towards 'Greed' and potentially boosting investor confidence and market activity.
- Strong Stock Performance: The Dow Jones surged over 500 points to close at 49,407.66, while the S&P 500 and Nasdaq gained 0.54% and 0.56%, respectively, reflecting a positive overall market trend.
- Positive Economic Data: The ISM Manufacturing PMI increased to 52.6 in January from 47.9, surpassing market expectations of 48.5, suggesting a rebound in manufacturing activity that could drive economic growth and improve corporate earnings outlook.
- Significant Stock Volatility: Despite Walt Disney Co. reporting better-than-expected quarterly results, its stock fell over 7%, and IDEXX Laboratories slid around 5% after issuing cautious guidance, indicating market concerns over individual company prospects.
See More
US Stocks Close Higher on Strong Manufacturing Data
- Manufacturing Index Surge: The US January ISM manufacturing index rose by 4.7 to 52.6, surpassing expectations of 48.5, marking the strongest expansion in over 3.25 years, which bolstered market optimism and contributed to stock gains.
- Chip Stocks Rally: Chipmakers and AI infrastructure stocks performed strongly on Monday, with Sandisk (SNDK) surging over 15% to lead the S&P 500 gainers, reflecting strong demand for tech stocks and a recovery in investor confidence.
- Energy Stocks Under Pressure: Energy producers faced headwinds as WTI crude oil prices fell more than 4%, with Diamondback Energy (FANG) and Occidental Petroleum (OXY) both declining over 3%, indicating growing concerns in the energy sector.
- Cryptocurrency Market Retreats: Bitcoin plummeted over 7% to a 9.75-month low, leading to widespread declines in cryptocurrency-related stocks, with Galaxy Digital Holdings (GLXY) and Strategy (MSTR) both dropping over 6%, reflecting weakened investor confidence in the crypto market.
See More
IDEXX Laboratories Reports Strong Q4 2025 Earnings Amid Target Revisions
- Strong Performance: IDEXX Laboratories reported Q4 2025 revenue of $1.09 billion, a 14% increase year-over-year, surpassing analyst expectations of $1.072 billion, demonstrating robust performance in the medical technology sector.
- Earnings Per Share Growth: The company’s earnings per share rose 18% to $3.08, exceeding the market estimate of $2.93, reflecting its sustained profitability and a gross margin of 61.7%.
- Core Business Growth: The companion animal segment grew 15% to $998 million, driven by strong instrument revenue, which surged 76% year-over-year, indicating robust market demand.
- Cautious Future Outlook: While IDEXX expects 2026 revenue between $4.63 billion and $4.72 billion, BTIG analysts noted a 200-basis-point drag from fewer pet visits among lower-income owners, although a 4% global price growth is anticipated.
See More
IDXX Options Trading Analysis and Risks
- Options Selling Risk: Selling puts on IDXX does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, necessitating careful risk-reward assessment.
- Yield Analysis: If IDXX's stock does not fall by 11.5%, the put seller only earns an 8.5% annualized return, with an effective cost basis of $540 per share after accounting for transaction costs.
- Historical Volatility: IDXX's historical volatility stands at 41%, and when combined with fundamental analysis, it aids investors in determining whether selling puts at the $560 strike price is worthwhile, balancing risks against potential rewards.
- Market Trading Dynamics: On Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
IDEXX Laboratories Reports Strong Q4 Results and 2026 Outlook
- Earnings Beat: IDEXX Laboratories reported Q4 2025 earnings of $3.08 per share, an 18% year-over-year increase that surpassed the consensus estimate of $2.94, indicating robust performance in the animal health sector.
- Sales Growth: The company achieved sales of $1.091 billion in Q4, exceeding the consensus of $1.073 billion and reflecting a 14% year-over-year growth, particularly driven by strong demand in the CAG Diagnostics segment.
- 2026 Outlook: IDEXX forecasts earnings per share for fiscal 2026 to be between $14.29 and $14.80, slightly above the consensus of $14.39, demonstrating confidence in future growth prospects.
- Analyst Rating Adjustments: BTIG analyst lowered the price target for IDEXX from $830 to $800 while maintaining a Buy rating, and UBS analyst reduced the target from $750 to $730 with a Neutral rating, reflecting a cautious market sentiment regarding the company's outlook.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
- Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
- Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
- Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
See More
Market Sentiment Improves as Stocks Rise
- Improved Market Sentiment: The CNN Money Fear & Greed Index rose to 61.2 on Monday from 56.1, indicating a shift towards 'Greed' and potentially boosting investor confidence and market activity.
- Strong Stock Performance: The Dow Jones surged over 500 points to close at 49,407.66, while the S&P 500 and Nasdaq gained 0.54% and 0.56%, respectively, reflecting a positive overall market trend.
- Positive Economic Data: The ISM Manufacturing PMI increased to 52.6 in January from 47.9, surpassing market expectations of 48.5, suggesting a rebound in manufacturing activity that could drive economic growth and improve corporate earnings outlook.
- Significant Stock Volatility: Despite Walt Disney Co. reporting better-than-expected quarterly results, its stock fell over 7%, and IDEXX Laboratories slid around 5% after issuing cautious guidance, indicating market concerns over individual company prospects.
See More
US Stocks Close Higher on Strong Manufacturing Data
- Manufacturing Index Surge: The US January ISM manufacturing index rose by 4.7 to 52.6, surpassing expectations of 48.5, marking the strongest expansion in over 3.25 years, which bolstered market optimism and contributed to stock gains.
- Chip Stocks Rally: Chipmakers and AI infrastructure stocks performed strongly on Monday, with Sandisk (SNDK) surging over 15% to lead the S&P 500 gainers, reflecting strong demand for tech stocks and a recovery in investor confidence.
- Energy Stocks Under Pressure: Energy producers faced headwinds as WTI crude oil prices fell more than 4%, with Diamondback Energy (FANG) and Occidental Petroleum (OXY) both declining over 3%, indicating growing concerns in the energy sector.
- Cryptocurrency Market Retreats: Bitcoin plummeted over 7% to a 9.75-month low, leading to widespread declines in cryptocurrency-related stocks, with Galaxy Digital Holdings (GLXY) and Strategy (MSTR) both dropping over 6%, reflecting weakened investor confidence in the crypto market.
See More
